



 <b>The Transplant Institute</b> METHODIST DALLAS Methodist Dallas Medical Center	<b>Title:</b> Transplanting Organs from COVID-19 Positive Donors	<b>Effective Date:</b> 11/29/2021
	<b>Section:</b> Kidney and Pancreas	
<b>Approved by:</b>  Alejandro Mejia, M.D., Executive Program Director, Transplantation  Edward Dominguez, M.D., Medical Director, Organ Transplant Infectious Disease  Tracy Giacoma, VP Transplant Services	<b>Revision Date(s):</b>	<b>Next review Date:</b> Subject to revision as the pandemic evolves and new data accumulate

**Purpose:** To describe the criteria and considerations for organ acceptance from donors with a history of COVID-19 and/or a positive SARS-COV-2 test at the time of organ recovery

**Definitions:**

- **Asymptomatic COVID-19 Infection:** Detection of SARS-CoV-2 in a nasopharyngeal (NP) sample without current symptoms compatible with COVID-19. **If a donor symptom history is unknown, they should be considered symptomatic.**
- **Mild COVID-19:** Positive NP sample in a donor with symptoms consistent with COVID-19 infection who did not require oxygen supplementation or inpatient hospitalization for COVID-19.
- **Severe COVID-19:** Positive NP sample in a donor with symptoms consistent with COVID-19 infection who required oxygen supplementation or inpatient hospitalization for COVID-19.
- **Resolved COVID-19:** An immunocompetent donor with a history of confirmed COVID-19, resolution of symptoms, more than 21 days from the date of onset of symptoms.

**Policy:**

Methodist Dallas Medical Center (MDMC) will consider the following offers:

- Offers from deceased donors with asymptomatic COVID-19 (as defined above) after obtaining a negative SARS-CoV-2 test by NAT in a lower respiratory sample (BAL)
- Offers from deceased donors with resolved COVID-19 (as defined above) after obtaining a negative BAL
- **MDMC will request BAL testing for all donors with a positive NP sample who are under consideration**
- Ultimately, organ acceptance will be at the discretion of the surgeon in consultation with ID while considering both donor & recipient characteristics, organ function and the risk vs benefit to the intended recipient

Methodist Dallas Medical Center (MDMC) will **not** consider the following offers:

- **Any deceased donor with a positive BAL sample**
- Deceased donors who are symptomatic (mild or severe) for COVID-19 at the time of evaluation by the organ procurement organization (OPO)
- Deceased donors with a positive SARS-COV-2 test at the time of evaluation, without prior known history of COVID-19 infection or with unknown symptom history
- Deceased donors of African American descent with a positive COVID-19 test at the time of evaluation due to increased risk of FSGS associated with the APOL-1 gene

**Recipient selection criteria:**

- Recipient must be fully vaccinated for COVID-19
- Willingness to accept such an organ and provide written informed consent

All recipients will be monitored closely for signs of COVID-19 and appropriate imaging and testing will be obtained in addition to the post transplant standard of care. Any suspected donor-derived infection will be reported per OPTN policy.

**References:**

1. <https://optn.transplant.hrsa.gov/media/kkhn1wah/sars-cov-2-summary-of-evidence.pdf>
2. Koval CE, Poggio ED, Lin YC, Kerr H, Eltemamy M, Wee A. Early success transplanting kidneys from donors with new SARS-CoV-2 RNA positivity: A report of 10 cases. *Am J Transplant.* 2021 Nov; 21(11):3743-3749. doi: 10.1111/ajt.16765. Epub 2021 Jul 23. PMID: 34254424; PMCID: PMC8441915.
3. Kates OS, Fisher CE, Rakita RM, Reyes JD, Limaye AP. Use of SARS-CoV-2-infected deceased organ donors: Should we always "just say no?". *Am J Transplant.* 2020 Jul; 20(7):1787-1794. doi: 10.1111/ajt.16000. Epub 2020 Jun 11. PMID: 32400087; PMCID: PMC7272824.
4. Meshram HS, Kute VB, Patel H, Desai S, Chauhan S, Dave RB. A case report of successful kidney transplantation from a deceased donor with terminal COVID-19-related lung damage: Ongoing dilemma between discarding and accepting organs in COVID-19 era! *Transpl Infect Dis.* 2021 Oct; 23(5):e13683. doi: 10.1111/tid.13683. Epub 2021 Jul 12. PMID: 34227197; PMCID: PMC8420099.
5. Sasmit Roy, Srikanth Kunaparaju, Narayana Murty Koduri, Vikram Sangani, Mytri Pokal, Venu Madhav Konala, Mamtha Balla, Sreedhar Adapa, "COVID-19 and APOL-1 High-Risk Genotype-Associated Collapsing Glomerulonephritis", *Case Reports in Nephrology*, vol. 2021, Article ID 3737751, 5 pages, 2021. <https://doi.org/10.1155/2021/3737751>
6. Wu H, Larsen CP, Hernandez-Arroyo CF, Mohamed MMB, Caza T, Sharshir M, Chughtai A, Xie L, Gimenez JM, Sandow TA, Lusco MA, Yang H, Acheampong E, Rosales IA, Colvin RB, Fogo AB, Velez JCQ. AKI and Collapsing Glomerulopathy Associated with COVID-19 and APOL1 High-Risk Genotype. *J Am Soc Nephrol.* 2020 Aug;31(8):1688-1695. doi: 10.1681/ASN.2020050558. Epub 2020 Jun 19. PMID: 32561682; PMCID: PMC7460910.